Lilly May Bid for Pfizer Animal Health Products, CFO Rice Says

Eli Lilly & Co. (LLY), whose top-selling antipsychotic drug Zyprexa faces generic competition in October, said it may bid for veterinary products being sold by Pfizer Inc. (PFE)

Lilly, which had $1.39 billion in sales from animal-health products last year, is monitoring Pfizer’s plans to divest its unit, Chief Financial Officer Derica Rice said in a conference call with investors today. The Indianapolis-based drugmaker will pursue any assets it deems of interest, Rice said.

To contact the reporter on this story: Tom Randall in New York at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.